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Abstract
The purpose of this research is to develop a new technique to synthesize a heterocyclic
arylidene compound using fruit puree catalysis and investigate its anti-cancer activity on
glioblastoma cancer cells. Recently, there has been interest in heterocycles due to their anticancer properties and they have been used in almost two-thirds of the novel molecular anticancer agents. Varying fruit purees were used to synthesize a novel hybrid arylidene pyrazolone
from 3-methyl-1-phenyl-5-pyrazolone and 4-dimethylaminobenzaldehyde by modifying
methodology developed by Dr. Murray. This arylidene pyrazolone was then tested for its anticancer activity on glioblastoma brain cancer cells using Dr. Smith’s 12-well cell viability assay.
The reagent and arylidene pyrazolone from two experiments that was tested for cell viability had
notable anti-cellular effects of varying potencies. In future studies, (a) more fruits could be tested
for their effectiveness in synthesis, (b) more arylidene pyrazolones can be synthesized, and (c)
both the fruit puree and the purified products can be tested to determine their efficacy in
inhibiting the initiation of tumors and for their anti-invasive properties.
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Introduction
Cancer is the second leading cause of death in the United States (National Center for
Health Statistics 2018). Brain cancer, however, is one of the most fatal forms, and can be caused
by tumors called gliomas. Gliomas, originating from the glial tissue in the brain or spine, make
up about 75% of malignant brain tumors and disrupt the support and function of neurons
(Guanarccia et al., 2018). Lack of properly functioning neurons affects the control of key brain
activities such as thinking, language, feeling, learning, memory, and all function and sensation
(Ludwig et al., 2019). According to the World Health Organization, there are several kinds of
gliomas characterized by the glial cell they are derived from such as astrocytomas (Louis et al.,
2001). Astrocytomas, the most malignant brain tumors, develop from connective, star-shaped
cells called astrocytes. Highly aggressive, grade IV astrocytomas are known as the cancer
glioblastoma multiforme. Glioblastoma multiforme (GBM) is the most common and fatal brain
cancer. Comprising 16 % of all primary brain and central nervous system cancers, glioblastoma
may occur in the brain as well as in the brain stem and spinal cord. The origin of glioblastoma
cancer cells remains a topic of controversy but has been hypothesized to have been caused by a
lineage of the tumor-initiating cells or inherited DNA mutations (Alcantara and Parada 2016).
Because glioblastoma begins as an asymptomatic tumor, when it can be diagnosed, the tumor has
already become highly aggressive and incurable (Davis 2016).
The lethality of glioblastoma is due to its aggressive progression and invasion, rapid
proliferation, and the challenge of the blood-brain barrier (Davis 2016). Unlike several other
cancers, the lack of complete aggregation of the tumor cells and local invasion are what makes
this cancer fatal (Holland 2000; Xie 2014). The tumor can grow quickly from an astrocytoma to
a grade IV glioblastoma by invading regions of the brain via connective fibers. Although it is
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rarely able to metastasize outside of the central nervous system, glioblastoma cancer cells invade
healthy brain tissues, making it impossible for conventional therapies to fully eradicate the
tumor. In addition, the blood-brain barrier, or the filtering mechanism of the capillaries that
transports blood to tissue in the brain and spinal cord, limits drug delivery to the brain (Sarkaria
2018).
Because of these challenges, the current multimodal approach for treatment has proven
unsuccessful. Current therapy first consists of maximal surgical resection without affecting the
surrounding healthy tissue as well as preserving neurological function (Kuhnt et al., 2016). This
is followed by radiation and chemotherapy with temozolomide (TMZ), a common anti-cancer
drug (Davis 2016). In addition to TMZ, five other drugs have been approved to aid in the
treatment of glioblastoma and act as DNA alkylators, kinase inhibitors, and tubulin inhibitors
(Shergalis 2018). However, despite these treatment options, the mean survival rate for a patient
with glioblastoma is 11-15 months (Ostrom et al., 2016; Xiao et al., 2017). The side effects
associated with these treatments, such as seizures and loss of cognitive function, diminish the
patient’s quality of life if they survive (Davis 2016). Furthermore, resistance to these modern
methods have become common, yielding them inefficient (Reardon et al., 2005).
Although there is no cure or permanent treatment therapy for glioblastoma, several
clinical trials have been conducted to in hopes of resolving this problem using molecularly
targeted therapeutics, personalized therapy using molecular profiling of individual tumors, and
immunotherapeutics. (Lieberman 2017). Complete resection of the tumor is the ultimate goal,
but the utilization of drugs to combat tumor formation has been the forerunner in research for
treatment (Kuhnt et al., 2016). In a recent study, scientists analyzed temozolomide,
bevacizumab, and a relatively new drug, sunitinib, and their effects on the proliferation and
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viability of glioblastoma cancer cells. They found that the newer drug, sunitinib, had a longer
lasting effect on obliterating the cancer cells in comparison to the other drugs, a helpful
discovery if it could be applied for long-term patient care (Guarnaccia et al., 2018). However,
although still in the early stages of development, sunitinib may have counterproductive side
effects: it has been associated with enhancing cancer invasiveness and metastasis due to its
toxicity (Hao 2016). Scientists are also studying other single protein targets and pathways like
tyrosine kinase receptor inhibitors of sunitinib to improve therapeutic options. However, these
inhibitors have been very expensive and had an emergence of resistance pathways by cancer
cells, causing their failure in late stages of GBM (Shergalis 2018).
Despite the strides made in recent research and understanding of this cancer, there has
still not been a drug therapy capable of sustainably combatting glioblastoma to improve the
survival of glioblastoma patients. However, exploration of 5-membered cyclic rings called
heterocycles has been popular. Heterocyclic compounds have shown antifungal, antiinflammatory, antibacterial, antioxidant, anticonvulsant, antiallergic, herbicidal and anticancer
properties (Al-Mulla 2017). Additionally, heterocyclic compounds have been used in almost
two-thirds of the novel molecular anti-cancer agents approved by the FDA from 2010-2015.
(Pearce 2017). This was largely attributed to their versatility in impacting many cellular
processes and metabolic pathways in cancer research (Pearce 2017). For example, heterocyclic
compounds have been useful in several pharmaceutical drugs such as temozolomide (Clemente
et al., 2018). Specifically, the derivatives of heterocyclic compounds such as indoles have been
evaluated for their anti-cancer abilities and are currently of high interest (Martins 2015).
Another class of derivatives of heterocycles are pyrazolones, nitrogen-based heterocycles
similar in structure to indoles. Nearly 60% of novel drugs contain this group; these drugs
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include analgesics, or drugs used to alleviate pain (Brogden 1986; Martins 2015). Pyrazolones
are also known to have antimicrobial, antioxidant, and anticancer activities (Sonia et al., 2013).
Because of these properties, pyrazolones could be useful in glioblastoma treatment. The
compound 3-methyl-1-phenyl-5-pyrazolone is a pyrazolone but to my knowledge, there have
been no studies published on this derivative of pyrazolones in reference to its potential as a target
anticancer agent, making it a compound of interest in the search for a viable glioblastoma drug
therapy.
Although heterocycle derivatives have promise in the search for glioblastoma therapy, the
combination of pyrazolones with aldehydes has seen success in previous research with
heterocyclic compounds. Aldehydes are used to synthesize hybrid compounds, in this case
arylidene pyrazolones, to create a stronger, more potent drug that will increase the antimicrobial,
and antioxidant properties (Sonia et al., 2013). In light of this, aldehydes such as 4dimethylaminobenzaldehyde, have been used in this research to use 3-methyl-1-phenyl-5pyrazolone to synthesize arylidene pyrazolone
Synthesis of the novel hybrid arylidene pyrazolone from 3-methyl-1-phenyl-5-pyrazolone
would be useful in the study of glioblastoma drug therapy not only to increase patient survival
but also improve environmental care. Current therapies utilize expensive and environmentally
toxic materials. A proposal to this problem would be created by varying the strategy for synthesis
using fruit puree as the catalyst for the reaction, a technique unique to my research. In this study,
I have utilized fruit puree as a catalyst for synthesizing drugs for cancer therapy experimentation
because fruits contain an abundance of enzymes (i.e. peroxidases, proteases) and potentially
provide a healthier alternative for the environment. This synthesis was conducted via the
mechanism of the Knoevenagel Condensation. This is a modification of the aldol condensation
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which involves the nucleophilic addition of a hydrogen compound to a carbonyl group followed
by a dehydration reaction, or the removal of a water molecule. The aldehyde group is eliminated
resulting in a α,β-unsaturated ketone. The elimination of this aldehyde indicates that the reaction
was successful.
The focus of this study is two-fold: a) synthesis of the arylidene product from the starting
material 3-methyl-1-phenyl-5-pyrazolone using fruit puree catalysis and by modifying Dr.
Murray’s methodology b) testing the starting material 3-methyl-1-phenyl-5-pyrazolone and the
novel hybrid on glioblastoma cancer cells to determine the LC50 (Lethal Concentration of 50%)
of the treated cells using Dr. Smith’s cell viability assay.
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Methods
Compound Synthesis
To synthesize the novel hybrid compound, I began with the procedure created by Dr.
Desmond Murray. I combined the following starting materials in a round bottom flask for
heating: the pyrazolone 3-methyl-1-phenyl-5-pyrazolone and an aldehyde 4dimethylaminobenzaldehyde. By combining this pyrazolone with this aldehyde, the novel
compound arylidene pyrazolone, a heterocyclic arylidene, was created using the Knoevenagel
condensation mechanism (Figure 1).
Three variables were adjusted to develop a more efficient and environmentally friendly
technique for synthesis of this novel hybrid compound: type of catalyst, time period for heating,
and type of solvent. Fresh fruit were selected to catalyze this reaction by researching their
enzymatic properties. Experiments were conducted using aloe vera (leaf), cucumber, avocado,
guava, broccoli mango, pineapple, and green apple. The enzyme papain, extracted from the
papaya fruit, was also used. In addition to fresh fruit, fermented mango and pineapple purees
were tested, fermented for over ~6 months. Each catalyst was tested to determine its ability to
yield a large amount of pure product. Secondly, the heating period was reduced from the original
duration of 3 hours to 1 hour. Completion of the experiment was determined by the solution’s
color change from yellow to a dark red color which indicates that a reaction has occurred.
Finally, the replacement of the solvent DMSO (dimethyl sulfoxide) with the solvent PEG-400
(polyethylene glycol) was tested. Although DMSO is not harmful in such a small quantity, largescale production of this drug could potentially have toxicity issues so DMSO was exchanged
with PEG-400, a less harmful and cheaper substance. During the heating procedure, the
temperature was carefully monitored between 50-55⁰C to prevent denaturing the enzyme.
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After heating, the mixture was stirred with saturated sodium chloride and liquid-liquid
extraction was used to separate the organic product, which contained the compound of interest,
from the aqueous liquid made up of water and water-based fruit particles. The organic liquid
product was then dried with solid sodium sulfate to remove leftover aqueous product and
vacuum distilled using a rotary evaporator to remove the solvent.
Analysis of hybrid compound
The final solid product was then weighed and analyzed using IR (Infrared Spectroscopy)
and NMR (Nuclear Magnetic Resonance) to determine if the desired functional groups of the
novel hybrid compound appear in the spectra (i.e. the disappearance of the aldehyde peak). To
perform NMR, the solvent chloroform-D was combined with the solid product.
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Figure 1. Knoevenagel condensation reaction equation for arylidene pyrazolone. Reaction of 3-methyl-1-phenyl-5pyrazolone with 4-dimethylamnobenzaldehyde to create arylidene pyrazolone.

Cell line and cell maintenance
The novel hybrid compound was tested on glioblastoma cancer cells of the cell line
U87MG. The cells were fed with MEM (Minimum Essential Medium) containing 10% fetal
bovine serum, penicillin, and streptomycin and incubated at 37˚C at 5% CO2 levels. Every 48hrs,
each cell plate was observed using a light microscope to note their density and growth. They
were also fed every 48hrs by providing new media and discarding 1ml of cells from each plate to
prevent overgrowth.
9

Testing compounds: Cell viability assay
Using Dr. Denise Smith’s protocol for glioblastoma cell viability testing over a 3-day
period, the effects of the reagent, 3-methyl-1-phenyl-5-pyrazolone, and the novel hybrid
compound were tested on the GBM cells. Before compound application, the old growth media
was removed from the plate and the cells were detached from the plate using trypsin, a digestive
enzyme that breaks down proteins in the small intestine. 10 microliters of this cell suspension
were combined with 90 microliters of trypan blue, a dye used to stain the dead cells so that the
living cells could be visible for counting. The number of living cells were counted using the
hemocytometer counting grid, a counting-chamber device that simplifies the cell counting
process (Figure 2).
The cells were then diluted in media so that the total number of cells was 10,000 in 1ml
of media. Each well of the 12-well plate received 10,000 cells/ml. The plate was incubated for
24hrs at 37⁰C at 5% CO₂ levels. After incubation, the media was removed from the wells. A
stock solution was created with 2mg of the novel hybrid compound and 1ml of DMSO. 1ml of
media was added to 12 1.5ml microcentrifuge tubes. The first tube was allocated to the first well
contained the highest concentration of the drug consisting of 200 microliters and an additional
800 microliters for a total volume of 2ml. Then, 1ml of this solution was removed and added to
the next tube. The same dilution will be performed for the all wells so that each contained half of
the amount of compound in the previous one as shown in Figure 3 (i.e. 2mg/ml, 1mg/ml,
0.5mg/ml, etc.).
After exactly 24hrs on day 3, the media containing the drug was removed and each well
was treated with 1ml of methanol for 5 minutes. The methanol was removed and then stained
with 1ml of crystal violet dye for another 5 minutes. After the crystal violet dye was removed
10

and the well plate was carefully washed with distilled water, the plate was left to dry for at least
48hrs before the cells were counted. The cells were counted by drawing 3 dots at the bottom of
each well, each equidistant from each other. The cells in the field of view of these dots were
counted once and averaged for each trial to get the cells per area.
The compound concentration will be considered successful if it is lethal to 50% of the
glioblastoma cells, otherwise known as calculating the LC50. In order to determine the LC50 of
each compound, a linear regression was used by plotting the concentration used on the x-axis and
the sum of number of cells killed for all the trials on the y-axis. Then, the tabulated equation was
used to solve for the concentration ‘x’ that will allow 50% of the cells to die by plugging in the
number that is half the maximum of cells that have died as the ‘y’ in the equation. This
calculation produced the predicted concentration that will be lethal to 50% of the cells given the
data collected. A t-test was conducted to determine the significance of the results.

Figure 2. The hemocytometer counting grid. The 5 darker shaded squares contain cells to be counted.

Figure 3. Cell viability assay on 12-well plate
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Results
Compound Synthesis
16 different experiments were conducted to create the novel heterocyclic hybrid and all
produced satisfactory IR and NMR spectroscopy, indicating purity (Table 1). It was determined
that the synthesis was successful without a catalyst, yielding approximately 22.6% yield.
However, upon addition of a fruit puree catalyst, the yield increased to a maximum of
approximately 95.9% with a fermented pineapple catalyst. Two procedures were conducted
using the solvents PEG-400 and the fermented fruit catalysts due to their high performance and
they yielded 63.4% (fermented mango catalyst) and 90.3% (fermented pineapple catalyst). Two
procedures were conducted reducing the heating time from 3 hours to 1 hour using the fermented
mango and fermented pineapple catalysts yielding 60.6% (fermented mango catalyst) and 95.9%
(fermented pineapple catalysts).
Table 1. This table displays the 16 compounds that were synthesized and what catalyst and solvent that were used as
well as their mass and percent yield.
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Cell viability assays
9 cell viability assays were conducted and analyzed testing the effects of the reagent 3methyl-1-phenyl-5-pyrazolone, fermented mango catalyzed compound (1hr heating) and
fermented pineapple catalyzed compound (1hr heating) on glioblastoma cancer cells, triplicates
performed for each compound. 15 cell viability assays were also conducted but have yet to be
analyzed, testing the compounds catalyzed by aloe vera, broccoli, guava, and avocado fruit
purees as well as the compound created without a catalyst. According to the linear regression, the
LC50 for the reagent 3-methyl-1-phenyl-5-pyrazolone is 0.69 mg/ml, 0.33 mg/ml for the
fermented pineapple catalyzed compound (1hr heating) and 0.13mg/ml for the fermented mango
catalyzed compound (1hr heating) as shown in in the cell viability graphs in Figure 4.
An independent t-test determined the significant results for each compound, indicated by
asterisks on the graphs. For the reagent 3-methyl-1-phenyl-5-pyrazolone, the significant results
were for the concentrations of 2 mg/ml, 1 mg/ml, 0.5 mg/ml, and 0.032 mg/ml (4A). For the
hybrid compound catalyzed by fermented pineapple (1hr heating), the significant results were for
concentrations of 2 mg/ml, 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.13 mg/ml, 0.063 mg/ml, and
0.078 mg/ml (4B). For the hybrid compound catalyzed by fermented mango (1hr heating), the
significant results were for all concentrations except 0.002 mg/ml (4C). Each graph followed a
steady inverse trend of increasing cell viability as the concentration of the drug decreased.
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B

C

14

Figure 4. Bar graphs depicting cell
mortality for compounds tested using
cell viability assays. On the y-axis lies
the concentration of the drug tested
with the final category being the
control. On the x-axis lies the cells
that remain alive after being treated
with the drug. The LC50 is indicated
by red arrow and asterisks indicate ttest significant results A. Cell viability
for reagent 3-methyl-1-phenyl-5pyrazolone. B. Cell viability for
fermented pineapple catalyst. C. Cell
viability for fermented mango
catalyst.

Discussion
Compound Synthesis
These results indicate not only is fruit puree a suitable catalyst for the synthesis of
arylidene pyrazolones, but fermented purees are most promising due to their greater yield
product. Fermentation causes an increase in the enzyme concentration which increases the
reaction rate. In turn, the substrate concentration is increased, and the yield product is greater.
This explains why the fermented catalysts (mango and pineapple) produced a higher percent
yield than the fresh fruit catalysts. Furthermore, the methodology saw comparable success with
the solvent PEG-400 as an alternative to DMSO and heating period could be reduced to 1hr.
Currently, this solvent is being used in several organic chemistry projects at the Andrews
University Department of Chemistry and Biochemistry as a result of this finding.
Not only was this procedure modified by the fruit puree used, heating time, and solvent,
but two unsuccessful methods were replaced. Originally, the purification process included the
boiling of the solution. However, the fruit product remained in the final compound, causing the
yield to exceed 100%, indicating impurity and confirmed by unsuccessful IR and NMR data.
Liquid-liquid extraction was a more successful alternative because it separated aqueous fruit
product from the organic layer containing the final compound resulting in satisfactory yield and
IR and NMR data. In addition, the previous vacuum distillation process was done via a funnel
and filter. However, this had proven to leave much of the final product behind on the filter paper,
skewing the results and diminishing the yield. Eliminating this method and using a rotary
evaporator remedied this problem.
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Compound Testing
Results from testing this hybrid compound on GBM cells show that the fruit puree
catalyzed compound had a lower LC50 than the reagent 3-methyl-1-phenyl-5, meaning the fruit
puree catalyzed hybrid compound is more successful in killing GBM cells that the original
pyrazolone. However, there are several points to be considered before assuming that this novel
compound alone is capable of killing cancer cells.
Because all 16 experiments were presumed to yield the same product based on IR and
NMR, it is reasonable to assume that each compound will yield same bioactivity results,
regardless of the fruit catalyst that was used. This is due largely to the fruit product being
removed from the end product during purification, meaning the fruit should not impact the cell
viability. Although the data may suggest this relationship, it is important to consider the purity of
the compound. In this study, purity analyses were based on IR and NMR spectroscopy, primarily
NMR as it possesses the higher sensitivity. However, the degree of purity should be called into
question. NMR has a high sensitivity of 300mHz, but it is not 100% sensitive - only up to
milligrams but not sensitive for micrograms of the compound (Subramanian and Webb 1998). In
other words, the lower the NMR sensitivity, the higher the possibility of failing to detect
impurities in the sample, and the NMR was unable to analyze the sample to the micrograms. In
addition, the synthesis of these compounds was completed 7 months prior to testing and IR and
NMR data were conduct at least 2 months prior to testing. The time between synthesis and
testing could also have an impact on whether there were impurities in the samples at the time the
cell viability assays were conducted. The data in this study shows that the fermented mango
catalyzed compound (0.13 mg/ml) had a significantly lower LC50 than the fermented pineapple
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catalyzed compound (0.33 mg/ml) which could be attributed to this issue of purity despite
successful IR and NMR tests.
Although the fruit puree should not be a factor in the mortality of GBM cells, it has not
yet been determined whether the fruit puree itself could have the ability to kill glioblastoma cells
independent of the compound. Studies show that mangoes possess anticancer properties as well
as anti-diabetic, anti-oxidant, anti-viral, and anti-inflammatory properties, to name a few (Parvez
2016). Pineapple extracts have also proven to have anticancer properties and investigations are
currently in place to challenge the proposal of its use as an agent against human cancer cells
paired with radiation therapy (Raeisi et al., 2018). It is likely that the fermented mango and
pineapple purees have the ability to kill cancer cells, but this would further emphasize lack of
purity in the novel hybrid compounds. To test this hypothesis, a cell viability assay could be run
to test purees themselves on GBM cells apart from the hybrid compound. For these reasons, this
study will be unable to conclude whether the fruit catalyzed hybrid compounds are the cause of
glioblastoma cell mortality.
Further Research
This study has provided multiple avenues for further research. In future studies for
synthesis of this heterocyclic compound, it would be imperative to focus on isolating the specific
enzymes acting on the reaction and their effect on product yield and purity. This is important
because although the same amount of fruit puree was allocated to each experiment, it is unknown
the amount or kinds of enzymes (other than peroxidases and proteases) that each fruit contains,
thus the enzymatic activity would vary. Pinpointing the enzyme of interest would help to further
standardize this procedure. It would also be interesting to conduct more experiments using the
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solvent PEG-400, other aldehydes, as well as other fruits, fresh and fermented, and analyze their
success in producing a pure product. In addition to IR and NMR, it would be necessary to
conduct chromatography, a process used to separate components of a mixture, not only to further
test the purity of these compounds but have a clearer picture of what other compounds may be
contributing to discrepancies that went undetected under NMR. This would clarify if there are
other compounds or fruit product remaining in the sample, especially prior to testing on GBM
cancer cells. Testing the fruit purees as well as the solvent PEG-400 on the cancer cells
independent of the compound would be a great next step in determining what is actually causing
this increase in cell mortality. Finally, further investigations could test the remaining compounds
for cell viability, as well as anti-invasiveness and tumor initiation, other concerns associated with
glioblastoma multiforme.
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